CB 618
Alternative Names: CB-238,618; CB-618Latest Information Update: 28 Feb 2018
At a glance
- Originator Cubist Pharmaceuticals
- Developer Merck & Co
- Class Antibacterials
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for phase-I development in Gram-negative-infections in USA (IV)
- 01 Apr 2015 Cubist Pharmaceuticals completes a phase-I clinical trial in Gram-negative infections in USA (IV) (NCT02341599)
- 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co